We have collected information about Peptide - And Aptamer-Functionalized Nanovectors For Targeted Delivery Of Therapeutics for you. Follow the links to find out details on Peptide - And Aptamer-Functionalized Nanovectors For Targeted Delivery Of Therapeutics.
https://asmedigitalcollection.asme.org/biomechanical/article/131/7/074005/400712/Peptide-and-Aptamer-Functionalized-Nanovectors-for
Targeted delivery of therapeutics is an area of vigorous research, and peptide- and aptamer-functionalized nanovectors are a promising class of targeted delivery vehicles. Both peptide- and aptamer-targeting ligands can be readily designed to bind a target selectively with high affinity, and more importantly are molecules accessible by chemical synthesis and relatively compact compared …Author: Todd O. Pangburn, Matthew A. Petersen, Brett Waybrant, Maroof M. Adil, Efrosini Kokkoli
https://experts.umn.edu/en/publications/peptide-and-aptamer-functionalized-nanovectors-for-targeted-deliv
N2 - Targeted delivery of therapeutics is an area of vigorous research, and peptide- and aptamer-functionalized nanovectors are a promising class of targeted delivery vehicles.Author: Todd O. Pangburn, Matthew A. Petersen, Brett Waybrant, Maroof M. Adil, Efrosini Kokkoli
https://www.researchgate.net/publication/26718192_Peptide-_and_Aptamer-Functionalized_Nanovectors_for_Targeted_Delivery_of_Therapeutics
Targeted delivery of therapeutics is an area of vigorous research, and peptide- and aptamer-functionalized nanovectors are a promising class of targeted delivery vehicles.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990390/
Aptamer-functionalized peptide H 3 CR 5 C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinomaAuthor: Ying Liu, Xin Wu, Yuan Gao, Jigang Zhang, Dandan Zhang, Shengying Gu, Guanhua Zhu, Gaolin Liu, Xiaoy...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765502/
Peptide-Functionalized Nanogels for Targeted siRNA Delivery. School of Chemistry and Biochemistry, Petit Institute for Bioengineering and Bioscience, School of Biology, and Ovarian Cancer Institute, Georgia Institute of Technology, Atlanta, Georgia 30332.Author: William H. Blackburn, Erin B. Dickerson, Michael H. Smith, John F. McDonald, L. Andrew Lyon
https://www.nature.com/articles/pj2012215
The authors prepared nanoparticles based on a polyacrylamide (PAA) nanoparticle core that combine a magnetic resonance imaging contrast enhancement, photodynamic therapy and specific targeting to tumor sites by using the F3 vascular homing peptide.Author: Antonella Accardo, Diego Tesauro, Giancarlo Morelli
https://www.sciencedirect.com/science/article/pii/S014181301836210X
Previous studies have showed that iRGD peptide facilitates uptakes of anticancer drugs by tumor cells specifically, and iRGD-functionalized antibodies and nanoparticles have increased anti-cancer efficacy [3,4]. The strategy of targeted delivery is especially necessary for delivery of RNA therapeutics including small interfering RNA (siRNA).Author: Tsogzolmaa Ganbold, Shuqin Han, Agula Hasi, Huricha Baigude
https://www.nature.com/articles/nrd.2016.199
Nov 03, 2016 · Nucleic acid aptamers, often termed 'chemical antibodies', are functionally comparable to traditional antibodies, but offer several advantages, including their relatively small physical size, flexible structure, quick chemical production, versatile chemical modification, high stability and lack of immunogenicity.Author: Jiehua Zhou, John Rossi
https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.7b00900
Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer Maryna Perepelyuk Department of Pharmaceutical Sciences, College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, United StatesAuthor: Maryna Perepelyuk, Koita Sacko, Karthik Thangavel, Sunday A. Shoyele
https://www.sciencedirect.com/science/article/pii/S0142961217305781
CRISPR/Cas9 is a versatile genome editing technology and holds tremendous promise for cancer treatment. However, a major bottleneck to achieve the therapeutic potential of the CRISPR/Cas9 is the lack of in vivo tumor-targeted delivery systems.Author: Chao Liang, Fangfei Li, Luyao Wang, Zong-Kang Zhang, Chao Wang, Bing He, Jie Li, Zhihao Chen, Atik B...
Searching for Peptide - And Aptamer-Functionalized Nanovectors For Targeted Delivery Of Therapeutics?
You can just click the links above. The data is collected for you.
